Theriva Biologics (TOVX)
XASE:TOVX
Want to see TOVX full AI Analyst Report?
TOVX Stock Chart & Stats
$0.20
-$0.06(-3.70%)
At close: 4:00 PM EST
$0.20
-$0.06(-3.70%)
Day’s Range― - ―
52-Week Range$0.16 - $0.86
Previous CloseN/A
Volume37.66K
Average Volume (3M)8.88M
Market Cap
$13.94M
Enterprise Value-$2.24M
Total Cash (Recent Filing)$14.43M
Total Debt (Recent Filing)$3.69M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-7.45
Enterprise Value/Gross Profit-8.10
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$2.50Price Target Upside1150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Bulls Say, Bears Say
Bulls Say
Regulatory Agreement For Phase 3FDA alignment on a pivotal Phase 3 design materially lowers regulatory execution risk and enables a clear pathway to a registrational trial. This durable outcome supports program planning, helps attract development funding or partners, and strengthens the company’s ability to pursue a biologics license if results are positive.
VCN-01 Phase 1 Translational DataMechanistic translational signals (stroma degradation, viral genomes in tumor, increased cytotoxic T-cells) provide scientific validation of the platform. Durable biological proof-of-mechanism lowers clinical development risk, increases credibility with investigators and partners, and supports broader indication expansion strategies.
Phase 2b VIRAGE Survival BenefitRandomized Phase 2b survival gains are a strong, durable signal that VCN-01 can provide clinical benefit in metastatic pancreatic cancer. Such outcome-level evidence underpins a credible registrational strategy, enhances partner and payer interest, and supports potential label-setting positioning if replicated in Phase 3.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow requires recurring external financing to fund trials and operations. Over a multi-month horizon this elevates dilution and execution risk, may force partnership/timing compromises, and limits flexibility to scale programs without securing committed capital.
Deep, Sustained LossesLarge, persistent losses have eroded equity and produced deeply negative ROE, reflecting value destruction. Over the medium term this undermines balance sheet resilience, increases dependency on dilutive financings or partnerships, and makes consistent investment in pivotal programs contingent on external funding.
Warrant Vote And Quorum DelaysRepeated quorum failures create procedural uncertainty around planned warrant-related share issuances that underpin financing. This prolongs timing and could disrupt capital plans, increasing the likelihood of alternative, potentially more dilutive funding or delays to trial starts until approvals or waivers are secured.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.16 and its highest was $0.86 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $13.94M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Aug 12, 2026 which is in 59 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on May 05, 2026. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.06.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 0.526%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
TOVX Stock 12 Month Forecast
Average Price Target
$2.50
▲(1150.00% Upside)
Technical Analysis
Ownership Overview
0.57%
Insiders
0.90% Mutual Funds
0.33% Other Institutional Investors
97.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---